267 related articles for article (PubMed ID: 12899783)
21. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Riley JP; Rosenberg SA; Parkhurst MR
J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
[TBL] [Abstract][Full Text] [Related]
22. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.
Xing Q; Pang XW; Peng JR; Yin YH; Li Y; Yu X; Zhou SP; Zhang Y; Chen WF
Biochem Biophys Res Commun; 2008 Jul; 372(2):331-5. PubMed ID: 18498761
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel HLA-A(*)0201-restricted CTL epitopes from Pokemon.
Yuan B; Zhao L; Xian R; Zhao G
Cell Immunol; 2012; 274(1-2):54-60. PubMed ID: 22405859
[TBL] [Abstract][Full Text] [Related]
24. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
[TBL] [Abstract][Full Text] [Related]
25. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
27. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.
Nijman HW; Houbiers JG; Vierboom MP; van der Burg SH; Drijfhout JW; D'Amaro J; Kenemans P; Melief CJ; Kast WM
Eur J Immunol; 1993 Jun; 23(6):1215-9. PubMed ID: 7684681
[TBL] [Abstract][Full Text] [Related]
28. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice.
Wentworth PA; Vitiello A; Sidney J; Keogh E; Chesnut RW; Grey H; Sette A
Eur J Immunol; 1996 Jan; 26(1):97-101. PubMed ID: 8566090
[TBL] [Abstract][Full Text] [Related]
29. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
[TBL] [Abstract][Full Text] [Related]
30. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
31. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals.
Thorn M; Tang S; Therrien D; Kløverpris H; Vinner L; Kronborg G; Gerstoft J; Corbet S; Fomsgaard A
APMIS; 2007 Jun; 115(6):757-68. PubMed ID: 17550385
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel CD8+ T cell epitope derived from cancer-testis antigen MAGE-4 in oesophageal carcinoma.
Wu ZY; Gao YF; Wu YH; Liu W; Sun M; Zhai MX; Qi YM; Ye Y
Scand J Immunol; 2011 Dec; 74(6):561-7. PubMed ID: 21815906
[TBL] [Abstract][Full Text] [Related]
33. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
35. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
36. [A HLA-A2-restricted-CTL epitope variation at the N-terminal of HCV helicase and the immune response of CTLs].
Guo HZ; Wang WL; Wang T
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):325-7. PubMed ID: 15193229
[TBL] [Abstract][Full Text] [Related]
37. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan.
Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC
J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312
[TBL] [Abstract][Full Text] [Related]
38. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry.
Zhou M; Peng JR; Zhang HG; Wang HX; Zhong ZH; Pan XY; Chen WF; Leng XS
Immunol Lett; 2005 Jun; 99(1):113-21. PubMed ID: 15885805
[TBL] [Abstract][Full Text] [Related]
39. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
[TBL] [Abstract][Full Text] [Related]
40. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
